SNOM-TECHNOLOGY
Snom Technology, the leading developer of professional and business IP Telephones, is proud to announce that they are now members of the ‘TeleTrusT Association of Germany’. Snom strives to achieve perfection in all aspects of its development with unparalleled craftsmanship, elegant design, practicality and interoperability. A prime example of Snom’s ongoing focus in the area of communications security is their ‘No Spyware Guarantee’ which has been reinforced with earning the “Security made in Germany” Quality Seal.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160609005553/en/
TeleTrusT is an association for IT security experts and facilitates information exchange between vendors, users and authorities. TeleTrusT comments on technical, political and legal issues related to IT security, and is an organizer of security related events and conferences. With a broad range of members and partner organizations, TeleTrusT embodies the largest competence network for IT security in Germany and Europe.
|
As a bearer of the TeleTrusT Quality Seal, Snom has proven their products are "IT Security made in Germany" and comply with the following requirements:
|
“We are proud to be part of TeleTrust competence network for IT security. Security presents a key differentiator for Snom and a critical aspect of our Precision German Engineering approach. By achieving the TeleTrusT Quality Seal, Snom further demonstrates its commitment. It also proves to our customers that they can have faith in our products.” commented Nadahl Shocair, CEO for Snom Technology AG.
About Teletrust
"ITSMIG" ("IT Security made in Germany") was established originally 2005 by the German Federal Ministries of the Interior and of Economics and Technology as well as by representatives of the German IT security industry. As a result of mutual consultations ITSMIG was in 2011 migrated to TeleTrusT.
The TeleTrusT Working Group "ITSMIG" aims to present IT security products, solutions and services "made in Germany" at national and international level working with industry partners, politics, authorities, organizations and science. They do this by emphasizing particular trustworthiness and have laid down criteria that are the basis for granting their quality seal.
About Snom Technology AG
Founded in 1997 and headquartered in Berlin Germany, Snom is a German multinational corporation and the world’s first and leading brand of professional and enterprise VoIP telephones. Snom operates wholly owned subsidiaries and branches in the United States, UK, France, Italy, Spain and Taiwan.
Snom’s German engineering is globally renowned for robust, high quality and feature-rich business telephones that are designed exclusively for the trained and certified professional IT and PBX installer. All of Snom’s products are universally compatible with leading PBX platforms operating under the SIP standard with over 4 million end-point installations globally. Snom products are sold through distributors to over 25,000 Snom Value Added Resellers across the world.
For more information, please visit www.snom.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160609005553/en/
Contact:
Snom Technology AG
Niclas Kakomanolis
PR Manager
press@snom.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom